ALX Oncology Holdings Inc., founded by industry veterans in South San Francisco, California, is a clinical-stage immuno-oncology company. Its core mission is to transform cancer treatment by developing evorpacept, a first-in-class foundational checkpoint immunotherapy. The company focuses on creating therapies that block CD47, a protein that cancer cells use to evade the immune system. ALX Oncology aims to maximize clinical activity while minimizing toxicities, targeting various oncology indications such as myelodysplastic syndromes, acute myeloid leukemia, and several types of carcinoma.

Notable affiliated people include its founding team of industry veterans with extensive experience in oncology and biotech. The company has attracted significant investment from leading venture capital firms specializing in life sciences. Key achievements include advancing evorpacept through clinical trials and demonstrating promising efficacy and safety profiles. ALX Oncology's innovative approach has the potential to significantly impact cancer treatment paradigms, offering new hope for patients with difficult-to-treat cancers.